New pill AVZO-023 takes on advanced breast cancer in first human trial
NCT ID NCT06998407
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests a new oral drug called AVZO-023, which blocks a protein (CDK4) that helps cancer cells grow. It is being tested alone or with other drugs in 380 adults with advanced solid tumors, especially a type of breast cancer called HR+/HER2-. The goal is to find a safe dose and see if it can shrink tumors.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
AVZO-023 (a CDK4 inhibitor drug taken by mouth)
What this could lead to
If successful, this could lead to a new treatment option for people with advanced breast cancer or other solid tumors that have stopped responding to current therapies.
What could go wrong
This is an early first-in-human study, so safety and effectiveness are not yet known. The drug may cause side effects or fail to shrink tumors, and results may not apply to all patients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Avenzo Therapeutics Recruiting Site
RECRUITINGLos Angeles, California, 90025, United States
Contact
-
Avenzo Therapeutics Recruiting Site
RECRUITINGLos Angeles, California, 90095, United States
Contact
-
Avenzo Therapeutics Recruiting Site
RECRUITINGNew Haven, Connecticut, 06519, United States
Contact
-
Avenzo Therapeutics Recruiting Site
RECRUITINGOrlando, Florida, 32827, United States
Contact
-
Avenzo Therapeutics Recruiting Site
RECRUITINGSarasota, Florida, 34232, United States
Contact
-
Avenzo Therapeutics Recruiting Site
RECRUITINGBoston, Massachusetts, 02215, United States
Contact
-
Avenzo Therapeutics Recruiting Site
RECRUITINGNew York, New York, 10016, United States
Contact
-
Avenzo Therapeutics Recruiting Site
RECRUITINGCleveland, Ohio, 44106, United States
Contact
-
Avenzo Therapeutics Recruiting Site
RECRUITINGColumbus, Ohio, 43221, United States
Contact
-
Avenzo Therapeutics Recruiting Site
RECRUITINGNashville, Tennessee, 37203, United States
Contact
-
Avenzo Therapeutics Recruiting Site
RECRUITINGFort Worth, Texas, 76104, United States
Contact
-
Avenzo Therapeutics Recruiting Site
RECRUITINGHouston, Texas, 77030, United States
Contact
-
Avenzo Therapeutics Recruiting Site
RECRUITINGSan Antonio, Texas, 78229, United States
Contact
-
Avenzo Therapeutics Recruiting Site
RECRUITINGFairfax, Virginia, 22031, United States
Contact